We are passionate about enabling more convenient solutions for patient centric sampling.

Since 2002, Attana research services and systems have improved their customers’ clinical trial success rates by 4x compared to the industry average. In 2021, they launched their first CE IVD-marked device for novel insights into antibody diagnostics. From a drop of blood (10µl), the AVA^TM laboratory system can both quantify the number of antibodies in a sample as well as determine their neutralizing capacity, in a matter of minutes. On 19th of May 2022, Attana announced an updated CE IVD marking for its AVA^TM SARS-CoV-2 IgG Immunoassay kit. This now includes capillary blood samples using Capitainer®qDBS which enables the technology to be used with self-sampling.

In combination with Capitainer® qDBS, Attana today offers high quality diagnostic analyses in a wider scope of studies than previously possible.

For more information visit www.attana.com

Altasciences is a forward-thinking, mid-size contract research organization strategically located across North-America, offering biopharmaceutical companies of all sizes a proven, flexible approach to preclinical and clinical studies, from lead candidate selection to proof of concept, and beyond. In addition to supporting clinical sites and preclinical testing facilities, their state-of-the-art bioanalytical laboratories provide stand-alone services for both small and large molecules.

With over 25 years of experience, Altasciences has a proven track record for delivering the accurate and precise drug concentrations that sponsors depend upon for successful regulatory submission. Keeping current in the evolving landscape of microsampling solutions for patient-centric healthcare and remote sampling, Altasciences’ evaluation of the Capitainer qDBS found the device straightforward to implement whilst being extremely capable of delivering accurate and precise blood volumes independent of hematocrit level. This allowed all precision and accuracy data for the quantitation of an anti-epileptic drug panel from dried blood spot to readily meet acceptance criteria as recently described at the AAPS (provide link here, which Capitainer should already have).

For more information visit www.altasciences.com

The University of Hertfordshire (UoH) is internationally recognised as the United Kingdom’s leading business-facing University. With a reputation for powering progress in academic and industrial research, we operate a hybrid bioanalytical and pharmaceutical analysis laboratory, with commercial services alongside academic research programmes. The primary focus is on the application of our Waters TQ-S micro and QTof systems to bioanalytical determinations of drugs and biomarkers in a wide range of matrices. The academic interests of UoH lie in the application and development of microsampling technologies.

The partnership with Capitainer focuses on the application of the qDBS technology to respiratory disease management, with the ability to volumetrically sample from a patient as a cornerstone of this. The overarching aim of this collaboration is to achieve an improvement in patient outcomes via monitoring in the remote setting, and driving uptake of novel disease management approaches.

Drug Delivery and Toxicology | Research | Uni of Herts

Capitainer AB and AstraZeneca R&D Gothenburg have initiated a research collaboration using a novel device from Capitainer. The new Capitainer^® CF card is capable of producing separated Cell-Free blood from a finger stick at the patients home. The sampling card automatically meters an exact volume of cell free blood and transfer it to a paper disc to produce a dried sample spot similar to dried plasma or serum. Transportation back to the laboratory can be performed at ambient temperature. The objective of this collaboration is to develop protocols for biomarkers relevant to AstraZeneca clinical drug programs based on the novel Capitainer^® CF card , enabling new patient centric sampling solutions to be implemented.

ProterixBio operates a high-complexity CLIA-certified lab in the Boston area which offers a range of services to support the development and validation of protein biomarker assays. Our CLIA lab houses a highly experienced assay development team that can assist with the optimization of extraction procedures and the validation of analytical methods. Our team is flexible and efficient, and excels at adapting commercially available immunoassay reagent-systems to fit-for-purpose performance in target populations. We have experience across a wide range of therapeutic areas and a diverse range of sample types, including patient-centric samples such as dried blood spots.

In collaboration with Capitainer, we would welcome the opportunity to assist other organizations looking to develop and validate patient-centric immunoassays under appropriate study conditions. Microsampling technologies such as that offered by Capitainer have the potential to improve patient access to accurate biomarker results through superior patient specimen collection, a possibility we look forward to accelerating by bringing our expertise to bear on your bespoke project needs.

High-Complexity CLIA Laboratory – Protein Assay Development Services – Remote Sample Collection % (proterixbio.com)